News

GAIA’s products are continuously examined in RCTs conducted by national and international research teams. Our news section is updated regularly.

GAIA Therapy Software Reduces Treatment Costs

Hamburg, Tuesday 18 September 2018 11.00 CEST

A high number of inpatient cases, hospitalization days and physician visits bloat healthcare spending without necessarily improving the quality of care. Therefore, RCT proven healthcare solutions that augment the quality of care while reducing treatment costs are needed.

Continue reading

Introducing GAIA’s Emyna® for Epilepsy – Therapy for a Better Quality of Life

Hamburg, Wednesday 25 July 2018 11.30 CEST

A randomized controlled trial (RCT) of Emyna with 200 people living with epilepsy has shown very encouraging results.

Emyna® (compound name EP28b) is GAIA’s fully automated therapeutic software designed to provide therapy for adults affected by epilepsy.

Continue reading

Compulsive Gamblers Successfully Treated with GAIA’s Therapy Software

Hamburg, Wednesday 13 June 2018 13.00 CEST

Significant reduction in gambling-related symptoms have been recorded following treatment with GAIA’s therapeutic software. Researchers from the University Medical Center Hamburg, Germany published the results last week.

Continue reading

GAIA presents: How to Heal Back Pain with Behavioral Change

Berlin, Monday 04 June 2018 12.00 CEST

Behavioral change is crucial for treating back pain. This message lies at the heart of our CEO’s presentation this Wednesday, at the 2018 Hauptstadt Kongress, Berlin. Dr. Mario Weiss, who is also the founder of GAIA, would be speaking...

Continue reading

GAIA Therapy Software Boosts Outpatient Care by a Factor of 2 - RCT Shows

Hamburg, Friday 18 May 2018 18.00 CEST

Can GAIA’s evidence-based therapy software improve the effectiveness of routine behavioral therapy? Yes! And a randomized controlled trial (RCT) has shown this.

This study was led by Swiss researchers, Professors Thomas Berger (Bern) and Andreas Maercker (Zürich). Collaboration with Germany’s...

Continue reading

Deprexis Launches in Brazil

Rio de Janeiro, Friday 13 April 2018 11.00 BRT

Deprexis has launched in Brazil! Deprexis is a fully-automated therapy for individuals suffering from depressive disorders.

According to the World Health Organization, Brazil has one of the highest numbers of people suffering from depression and anxiety. GAIA AG...

Continue reading

Clinical Trial shows GAIA’s Elevida Reduces Fatigue in Multiple Sclerosis

Hamburg, Tuesday 27 March 2018 09.00 GMT

GAIA’s fully automated therapy software, Elevida, reduces Multiple Sclerosis (MS) related fatigue in patients, a randomized controlled trial (RCT) has confirmed. Results were published recently by the internationally acclaimed British Medical Journal (BMJ).

Continue reading

Major Payer, DAK Gesundheit and GAIA Partner to Treat Back-Pain

Berlin, Thursday 15 March 2018 11.45 GMT

Our partnership with DAK Gesundheit, a leading German health insurer, has been extended with the launch of Rücken@Fit. Rücken@Fit is a digital therapeutic we developed in conjunction with AIRBUS to help people manage back-pain.

Continue reading

Cost-Effectiveness is not a “Class Effect” of Digital Therapeutics

Hamburg, Thursday 22 February 2018 09.15 CET

A recent meta-analysis reveals that beyond clever marketing, several guided internet-based interventions fail to deliver cost effectiveness. Thus, it turns out that cost-effectiveness is not a “class effect” in digital therapeutics. Meaning, not all digital therapeutics are automatically cost-effective.

Continue reading

The United Arab Emirates adopts GAIA’s Therapy Software to Treat MS

Dubai, Tuesday 30 January 2018 17.35 CET

The United Arab Emirates (UAE) will now use deprexis MS, GAIA’s digital therapy software, to treat depression in multiple sclerosis (MS) patients.

Government officials made this announcement at the ongoing Arab Health Exhibition and Conference in Dubai, which runs until...

Continue reading

GAIA Therapy Software Enhances Inpatient Treatment Efficacy

Munich, Monday 15 January 2018 06.35 CET

A randomized controlled trial (RCT) has provided powerful evidence that adding our digital software significantly improves inpatient treatment efficacy. This clinical study was conducted by leading, independent researchers at the University Medical Center Mainz, Germany. The results have been published...

Continue reading

GAIA presents at the Biotech Showcase Annual Conference on January 8th

San Francisco, Tuesday 02 January 2018 10.00 PST

GAIA AG will present at the 2018 Biotech Showcase ™ to be held January 8 – 10 at the Hilton San Francisco Union Square. This is arguably one of the most important weeks in healthcare investor congresses.

Continue reading

Empowering Patients with MS: Federal Joint Committee funds Project involving GAIA Innovation

Berlin, Friday 15 December 2017 09.05 GMT

Can digital therapeutic interventions empower multiple sclerosis (MS) patients to better cope with symptom flare-ups? Can digital therapy software help reduce inflammation? Can such solutions prevent relapses and improve quality of life?

Continue reading

GAIA’s Digital Therapy Reduces Health Insurance Costs – Economic Evaluation shows

Glasgow, UK, Thursday 30 November 2017 07.25 GMT

A new study confirms that deprexis® reduces total health insurance costs. GAIA’s leading digital therapy software is proven to facilitate reliable reduction of symptoms.

These findings were presented at the annual European Congress of ISPOR (the International Society for Pharmacoeconomics...

Continue reading

Consumer Testimony Highlights Deprexis on Tagesschau

Hamburg, Thursday 29 November 2017 06.35 GMT

Leading German news programme, Tagesschau has showcased consumer testimony highlighting the immense help GAIA’s fully automated therapy software is for patients.

In the news clip, Nicole Weissenfels-Boller an individual diagnosed with depression notes how convenient the treatment is. Nicole says...

Continue reading

Join our Digital Therapy Webinar on Sep. 20, 2017!

Hamburg, Wednesday 16 August 2017 10.22 CST

Digital therapy is radically reshaping the healthcare landscape for a number of key reasons: Well-developed digital therapeutics can be as effective as chemical compounds. Distribution and production costs are very low. In addition, real life data are collected from every...

Continue reading

Meta-analysis confirms effectiveness of GAIA’s digital therapy

Oxford, UK, Friday 28 July 2017 11.09 GMT

A meta-analysis of GAIA’s digital therapy for depression (deprexis) has been published in the latest issue of the peer-reviewed scientific journal Psychiatry Research. First-authored by Dr. Conal Twomey from the University College Dublin, the meta-analysis included 8 randomized controlled trials...

Continue reading

Long-term effectiveness of GAIA digital therapy shown in new study

Exeter, UK, Wednesday 19 July 2017 14:19 GMT

In a new article coming out in Behaviour Research and Therapy, a team of leading researchers reported that one of GAIA’s digital therapies is effective at one-year follow-up, nine months after the treatment had actually ended. The benefits conferred by...

Continue reading

World Congress of Psychiatry, Berlin 2017 – GAIA research in the spotlight

Berlin, Thursday 20 April 2017 11.43 CST

Two GAIA-chaired symposia have been accepted by the Scientific Programme Committee of the World Congress of Psychiatry, to be held in Berlin from October 8th to 12th, 2017. In the first symposium, scientists from the University College Dublin, Ireland, will...

Continue reading

GAIA´s plexus® intervention improves prescription behavior of physicians in ambulatory care

Berlin, Tuesday 18 April 2017 15.45 CST

Optimizing physicians’ prescription behavior in ambulatory care settings can be a challenge – particularly if the physicians are working in independent private practices. GAIA used its digital behavior-change competence to empower physicians working in such settings to make better (=more...

Continue reading

GAIA antidepressant digital therapy (deprexis) effective in the US

Austin, Texas, Friday 24 February 2017 13.36 CST

A randomized controlled trial with N = 376 depressed adults, published in the latest issue of the Journal of Consulting and Clinical Psychology, has confirmed that deprexis is effective in the United States. The trial was led by Professor Christopher...

Continue reading

JAMA Psychiatry meta-analysis confirms deprexis efficacy

Amsterdam, Wednesday 22 February 2017 17.45 GMT

A new meta-analysis of individual patient data, published in the latest issue of JAMA Psychiatry, confirmed the efficacy of deprexis for the treatment of depression. The software is one of GAIA’s developments. It has recently been licensed to Servier globally,...

Continue reading

Servier and GAIA extend their deprexis partnership

Hamburg, Tuesday 14 February 2017 18.00 GMT

Servier, the independent international pharmaceutical company, and GAIA, a global pioneer in digital therapy, have signed a partnership to extend the marketing of deprexis®.

Although depression is a widespread condition, with approximately 350 million individuals affected globally (WHO), many patients...

Continue reading

Deprexis as adjunctive treatment tool for psychotherapists?

Berlin, Friday 27 January 2017 17.00 GMT

A randomized controlled trial examined whether experienced psychotherapists can use one of GAIA’s interventions (Deprexis) to augment or enhance their normal depression treatment. The study was conducted over several years and directed by leading psychotherapy researchers in Switzerland (Professor Berger,...

Continue reading

Gaia AG at the Digital Medicine Showcase

San Francisco, Thursday 5 January 2017 15.00 GMT

We are pleased to announce that Gaia AG will present at the Digital Medicine Showcase 2017, as part of the Bio Tech Showcase, on January 10, 2017 at 10:15am.

Continue reading

Work-related psychotherapy

Hamburg, Wednesday 4 January 2017 10.00 GMT

GAIA has contributed a chapter on internet-based interventions for work-related mental disorders, which was recently published in the book “Arbeitsplatzbezogene Psychotherapie” (work-related psychotherapy) by Professor Kai Kahl and Lotta Winter. The chapter provides an overview of the evidence in this...

Continue reading

Deprexis effective in USA

Austin, Texas, Monday 12 December 2016 18.30 GMT

A randomized controlled trial with N = 376 adults with at least moderately severe depression has confirmed that Deprexis is effective in the United States. The trial was led by Professor Christopher Beevers at the University of Texas, Austin. With...

Continue reading

Reducing risky and harmful drinking

Hamburg, Friday 9 December 2016 14.30 GMT

A randomized controlled trial testing the efficacy of vorvida, our intervention for adults trying to reduce excessive alcohol consumption, has recently been completed. Data are currently being analysed and results are expected to be available in early 2017. The study...

Continue reading

GAIA in San Francisco

Hamburg, Tuesday 6 December 2016 9.00 GMT

Mario Weiss (CEO GAIA) and Michael Nick ( EVP Business Development) will attend the 35th annual JP Morgan Healthcare Conference and present at the Digital Medicine Showcase on January 10 at 10:15. We look forward to seeing you there.

Continue reading

Effective treatment for MS fatigue

Hamburg, Friday 2 December 2016 11.15 GMT

Elevida, our cognitive-behavioural therapy software for patients with multiple sclerosis has been demonstrated to be effective in a randomized controlled trial with 275 patients, led by researchers at the Institute of Neuroimmunology, University Medical Center Hamburg-Eppendorf. Over the course of...

Continue reading

Sanitas

Zurich, Thursday 10 November 2016 16.00 GMT

The Sanitas health insurance, covering almost 10% of the Swiss population, has been awarded the Innovation Award 2016 of the Swiss health insurance industry for their “Psychological Balance” programme, which offers a comprehensive suite of GAIA’s digital therapeutics for their...

Continue reading

Effective anxiety reduction

Bern, Monday 12 September 2016 10.00 GMT

After nearly four years of research and development, we are proud to announce that velibra, our digital therapy software for anxiety disorders, has demonstrated efficacy in a high quality randomized controlled trial. The trial’s Principal Investigator, Prof. Thomas Berger, concluded...

Continue reading

deprexis24

Hamburg, Monday 15 August 2016 11.30 GMT

The French pharma company and GAIA entered into a marketing and sales cooperation for deprexis in Germany. Servier will promote deprexis under the brand name deprexis24 as an innovative addition to their product portfolio in neurology and psychiatry.

Continue reading

Veovita

Hamburg, Saturday 30 April 2016 12.30 GMT

Veovita and the DAK-G statutory health insurance today reached an agreement that will help thousands of people getting faster and better coordinated access to medical help for their mental disorders. As an additional benefit, GAIA’s latest digital therapeutics will play...

Continue reading

Deprexis in Italian and Portuguese

Hamburg, Thursday 21 January 2016 10.30 GMT

Deprexis in Italian and Portuguese: Deprexis is now available in Italian and Portuguese/Brazilian. These newly translated were developed by GAIA in the context of the “Nevermind” project, an international research and development project funded by the European Commission under the...

Continue reading

Sanitas

Zurich, Saturday 12 December 2015 09.30 GMT

GAIA and the Swiss statutory health insurance today signed a comprehensive cooperation agreement that will help Sanitas to leverage the opportunities of effective and safe digital therapeutics among their insured people.

Continue reading